Seeking Alpha: Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene ...
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Business Insider: Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
DALLAS, (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus ...
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript Taysha Gene Therapies, Inc. beats earnings expectations. Reported EPS is $-0.08711, expectations were ...
Nasdaq: Taysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific Meeting
Taysha Gene Therapies, Inc. announced key updates on its TSHA-102 program, an investigational gene therapy for Rett syndrome, at the upcoming 2025 International Rett Syndrome Foundation Scientific ...
Taysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific Meeting
Taysha Gene Therapies faces the potential delisting of its shares for trading below their required minimum price—the latest in a series of setbacks for the Dallas-based company, which recently ...
Seeking Alpha: Taysha: The FDA Just Stuck A Major Blow To Their Plans
Taysha has a good chance of scoring with the GAN indication. Astellas may license this program if that happens. However, the FDA's request for more patients is a critical problem. Looking for more ...